BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14726072)

  • 1. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer.
    Port JL; Kent MS; Korst RJ; Keresztes R; Levin MA; Altorki NK
    Ann Thorac Surg; 2004 Jan; 77(1):254-9; discussion 259. PubMed ID: 14726072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
    Cerfolio RJ; Ojha B; Mukherjee S; Pask AH; Bass CS; Katholi CR
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):938-44. PubMed ID: 12698159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
    Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
    Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
    Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.
    Al-Sarraf N; Aziz R; Gately K; Lucey J; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):104-9. PubMed ID: 17977738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
    De Leyn P; Stroobants S; De Wever W; Lerut T; Coosemans W; Decker G; Nafteux P; Van Raemdonck D; Mortelmans L; Nackaerts K; Vansteenkiste J
    J Clin Oncol; 2006 Jul; 24(21):3333-9. PubMed ID: 16849747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.
    Lin JT; Yang XN; Zhong WZ; Liao RQ; Dong S; Nie Q; Weng SX; Fang XJ; Zheng JY; Wu YL
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):914-919. PubMed ID: 27113090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
    Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
    Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.
    Pepek JM; Marks LB; Berry MF; Ready NE; Gee NG; Coleman RE; D'Amico TA; Crawford J; Kelsey CR
    Pract Radiat Oncol; 2015; 5(2):79-84. PubMed ID: 25413417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
    Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
    Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
    J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion positron emission/computed tomography underestimates the presence of hilar nodal metastases in patients with resected non-small cell lung cancer.
    Carrillo SA; Daniel VC; Hall N; Hitchcock CL; Ross P; Kassis ES
    Ann Thorac Surg; 2012 May; 93(5):1621-4. PubMed ID: 22429676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of integrated positron emission tomography and computed tomography in the assessment of nodal spread in cases with non-small cell lung cancer.
    Tasci E; Tezel C; Orki A; Akin O; Falay O; Kutlu CA
    Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):200-3. PubMed ID: 19933240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.
    Akhurst T; Downey RJ; Ginsberg MS; Gonen M; Bains M; Korst R; Ginsberg RJ; Rusch VW; Larson SM
    Ann Thorac Surg; 2002 Jan; 73(1):259-64; discussion 264-6. PubMed ID: 11834020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.